PTO/SB/08A (01-08)

Approved for use through 03/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1695, no persons are regioned to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 10/580.984 INFORMATION DISCLOSURE Filing Date May 25, 2006 STATEMENT BY APPLICANT First Named Inventor **Curtis Dobson** Art Unit To be assigned (Use as many sheets as necessary) To be assigned Examiner Name Sheet of 81599-2 Attorney Docket Number

U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan		
Initials *	Cite No. ¹	Number - Kind Code ² (if known)			Passages or Relevant Figures Appear		
		US-					
		US-					
		US-					
		US-					
*		US-					
-		US-					
		US-	-				
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
•		US-					
		UŞ-					
		US-					
		US-					
	1	US-					

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant				
	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁸			
	1	WO94/04177	03-03-1994	The Rogosin Institute					
-									

Examiner Signature		Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO					Complete if Known		
			D 10	OL COLIDE	Application Number	10/580,984	
				CLOSURE	Filing Date	May 25, 2006	
	STAT	EMENT B	ΥA	PPLICANT	First Named Inventor	Curtis Dobson	
					Art Unit	To be assigned	
(Use as many sheets as necessary)				necessary)	Examiner Name	To be assigned	
abla	Sheet	2	of	2	Attorney Docket Number	81599-2	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	Azuma et al., A Synthetic Peptide Of Human Apoprotein E With Antibacterial Activity, Peptides, (2000), pp. 327-330, 21.	
	2	Clay et al., Localization Of A Domain In Apolipoprotein E With Both Cytostatic And Cytotoxic Activity, Biochemistry, (1995), pp. 11142-11151, 34.	
	3	Owens et al., Apolipoprotein A-I And Its Amphipathic Helix Peptide Analogues Inhibit Human Immunodeficiency Virus-Induced Syncytium Formation, Journal of Clinical Investigations, (October 1990), pp. 1142-1150, 86.	
	4	Srinivas et al., Inhibition Of Virus-Induced Cell Fusion By Apolipoprotein A-I and Its Amphipathic Peptide Analogs, Journal Of Cellular Biochemistry, (1991), pp. 224-237, 45.	
			

Examiner	 Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.